Click Here for 5% Off Your First Aladdin Purchase!

Tivantinib (ARQ 197) - 98%, high purity , Hepatocyte growth factor receptor inhibitor, CAS No.905854-02-6, Hepatocyte growth factor receptor inhibitor

  • Moligand™
  • ≥98%
Item Number
T127502
Grouped product items
SKUSizeAvailabilityPrice Qty
T127502-5mg
5mg
In stock
$39.90
T127502-10mg
10mg
In stock
$69.90
T127502-25mg
25mg
In stock
$129.90
T127502-50mg
50mg
In stock
$199.90
T127502-100mg
100mg
In stock
$299.90
T127502-250mg
250mg
In stock
$659.90

Basic Description

SynonymsTivantinib|905854-02-6|ARQ-197|ARQ 197|(3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione|Tivantinib (ARQ 197)|ARQ197|905853-99-8|1000873-98-2|rel-(3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1
Specifications & PurityMoligand™, ≥98%
Biochemical and Physiological Mechanisms

Tivantinib is an orally available, small molecule inhibitor of the c-Met receptor tyrosine kinase.

Storage TempStore at -20°C,Argon charged
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionHepatocyte growth factor receptor inhibitor

Product Properties

ALogP2.9

Associated Targets

CTDNEP1 Tbio CTD nuclear envelope phosphatase 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CDK1 Tchem Cyclin-dependent kinase 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

EPHB6 Tchem Ephrin type-B receptor 6 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

EGFR Tclin Epidermal growth factor receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

DNAJA1 Tchem DnaJ homolog subfamily A member 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CDK9 Tchem Cyclin-dependent kinase 9 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CDK16 Tchem Cyclin-dependent kinase 16 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CDK4 Tclin Cyclin-dependent kinase 4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CDK17 Tchem Cyclin-dependent kinase 17 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CDK2 Tchem Cyclin-dependent kinase 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CDK5 Tchem Cyclin-dependent-like kinase 5 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SRC Tclin Proto-oncogene tyrosine-protein kinase Src 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

YES1 Tclin Tyrosine-protein kinase Yes 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

TYK2 Tclin Non-receptor tyrosine-protein kinase TYK2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HDAC6 Tclin Histone deacetylase 6 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

FLT3 Tclin Receptor-type tyrosine-protein kinase FLT3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

FGFR1 Tclin Fibroblast growth factor receptor 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MET Tclin Hepatocyte growth factor receptor 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

IGF1R Tclin Insulin-like growth factor 1 receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SIK2 Tchem Serine/threonine-protein kinase SIK2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PLK4 Tchem Serine/threonine-protein kinase PLK4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PIM1 Tchem Serine/threonine-protein kinase pim-1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PIM2 Tchem Serine/threonine-protein kinase pim-2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PDGFRB Tclin Platelet-derived growth factor receptor beta 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MCM4 Tchem DNA replication licensing factor MCM4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MAP2K2 Tclin Dual specificity mitogen-activated protein kinase kinase 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MAP4K5 Tchem Mitogen-activated protein kinase kinase kinase kinase 5 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

BMPR1B Tchem Bone morphogenetic protein receptor type-1B 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

BTK Tclin Tyrosine-protein kinase BTK 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AURKA Tchem Aurora kinase A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AURKB Tchem Aurora kinase B 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AAK1 Tchem AP2-associated protein kinase 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

TNK2 Tclin Activated CDC42 kinase 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ACAD10 Tchem Acyl-CoA dehydrogenase family member 10 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ABL1 Tclin Tyrosine-protein kinase ABL1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AKT3 Tchem RAC-gamma serine/threonine-protein kinase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AKT2 Tchem RAC-beta serine/threonine-protein kinase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AKT1 Tchem RAC-alpha serine/threonine-protein kinase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CHEK1 Tchem Serine/threonine-protein kinase Chk1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CLK3 Tchem Dual specificity protein kinase CLK3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CLK1 Tchem Dual specificity protein kinase CLK1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CLK2 Tchem Dual specificity protein kinase CLK2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CLK4 Tchem Dual specificity protein kinase CLK4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

GSK3B Tclin Glycogen synthase kinase-3 beta 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

GSK3A Tclin Glycogen synthase kinase-3 alpha 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NTRK1 Tclin High affinity nerve growth factor receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MAP2K1 Tclin Dual specificity mitogen-activated protein kinase kinase 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

Pubchem Sid488197553
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/488197553
IUPAC Name (3R,4R)-3-(1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione
INCHI InChI=1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,19-20,24H,4,6,10H2,(H,25,27,28)/t19-,20-/m0/s1
InChi Key UCEQXRCJXIVODC-PMACEKPBSA-N
Canonical SMILES C1CC2=C3C(=CC=C2)C(=CN3C1)C4C(C(=O)NC4=O)C5=CNC6=CC=CC=C65
Isomeric SMILES C1CC2=C3C(=CC=C2)C(=CN3C1)[C@H]4[C@@H](C(=O)NC4=O)C5=CNC6=CC=CC=C65
PubChem CID 11494412
Molecular Weight 369.42

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

19 results found

Lot NumberCertificate TypeDateItem
A2411392Certificate of AnalysisDec 16, 2023 T127502
A2411375Certificate of AnalysisDec 16, 2023 T127502
A2411374Certificate of AnalysisDec 16, 2023 T127502
A2411373Certificate of AnalysisDec 16, 2023 T127502
A2219439Certificate of AnalysisNov 10, 2023 T127502
A2219743Certificate of AnalysisNov 10, 2023 T127502
A2219695Certificate of AnalysisNov 10, 2023 T127502
A2219435Certificate of AnalysisNov 10, 2023 T127502
C23241005Certificate of AnalysisFeb 03, 2023 T127502
C23241009Certificate of AnalysisFeb 03, 2023 T127502
C23241010Certificate of AnalysisFeb 03, 2023 T127502
C23241011Certificate of AnalysisFeb 03, 2023 T127502
C23241018Certificate of AnalysisFeb 03, 2023 T127502
C23241124Certificate of AnalysisFeb 03, 2023 T127502
C2324973Certificate of AnalysisFeb 03, 2023 T127502
C2324976Certificate of AnalysisFeb 03, 2023 T127502
C2324979Certificate of AnalysisFeb 03, 2023 T127502
A2219742Certificate of AnalysisJan 04, 2022 T127502
A2219696Certificate of AnalysisJan 04, 2022 T127502

more

Chemical and Physical Properties

SolubilityDMSO 74 mg/mL Water <1 mg/mL Ethanol 40 mg/mL

Safety and Hazards(GHS)

Pictogram(s) GHS08
Signal Danger
Hazard Statements

H373:Causes damage to organs through prolonged or repeated exposure

H360:May damage fertility or the unborn child

Precautionary Statements

P280:Wear protective gloves/protective clothing/eye protection/face protection.

P405:Store locked up.

P501:Dispose of contents/container to ...

P260:Do not breathe dust/fume/gas/mist/vapors/spray.

P203:Obtain, read and follow all safety instructions before use.

P318:if exposed or concerned, get medical advice.

P319:Get medical help if you feel unwell.

Related Documents

References

1. Danilkovitch-Miagkova A, Zbar B.  (2002)  Dysregulation of Met receptor tyrosine kinase activity in invasive tumors..  J Clin Invest,  109  (7): (863-7).  [PMID:11927612]
2. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF.  (2003)  Met, metastasis, motility and more..  Nat Rev Mol Cell Biol,  (12): (915-25).  [PMID:14685170]
3. Boccaccio C, Comoglio PM.  (2006)  Invasive growth: a MET-driven genetic programme for cancer and stem cells..  Nat Rev Cancer,  (8): (637-45).  [PMID:16862193]
4. Munshi N, Jeay S, Li Y, Chen CR, France DS, Ashwell MA, Hill J, Moussa MM, Leggett DS, Li CJ.  (2010)  ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity..  Mol Cancer Ther,  (6): (1544-53).  [PMID:20484018]
5. Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE, Orlov S et al..  (2011)  Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer..  J Clin Oncol,  29  (24): (3307-15).  [PMID:21768463]
6. Katayama R, Aoyama A, Yamori T, Qi J, Oh-hara T, Song Y, Engelman JA, Fujita N.  (2013)  Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition..  Cancer Res,  73  (10): (3087-96).  [PMID:23598276]
7. Rimassa L, Bruix J, Broggini M, Santoro A.  (2013)  Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--letter..  Clin Cancer Res,  19  (15): (4290).  [PMID:23766362]

Solution Calculators